[go: up one dir, main page]

BRPI0506736A - composto estereoisoméricos e métodos para o tratamento de distúrbios gastrointestinais e no sistema nervoso central - Google Patents

composto estereoisoméricos e métodos para o tratamento de distúrbios gastrointestinais e no sistema nervoso central

Info

Publication number
BRPI0506736A
BRPI0506736A BRPI0506736-7A BRPI0506736A BRPI0506736A BR PI0506736 A BRPI0506736 A BR PI0506736A BR PI0506736 A BRPI0506736 A BR PI0506736A BR PI0506736 A BRPI0506736 A BR PI0506736A
Authority
BR
Brazil
Prior art keywords
nervous system
central nervous
gastrointestinal
treatment
methods
Prior art date
Application number
BRPI0506736-7A
Other languages
English (en)
Inventor
Ian Irwin
Monica Palme
Cyrus Becker
Original Assignee
Aryx Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aryx Therapeutics filed Critical Aryx Therapeutics
Publication of BRPI0506736A publication Critical patent/BRPI0506736A/pt
Publication of BRPI0506736B1 publication Critical patent/BRPI0506736B1/pt
Publication of BRPI0506736B8 publication Critical patent/BRPI0506736B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)

Abstract

COMPOSTOS ESTEREOISOéRICOS E MéTODOS PARA O TRATAMENTO DE DISTúRBIOS GASTROINTESTINAIS E NO SISTEMA NERVOSO CENTRAL. A presente invenção fornece compostos estereoisoméricos de fórmula (x): onde as variáveis são definidas neste relatório descritivo e as composições para o tratamento seguro e eficiente de várias doenças gastrointestinais incluindo, a título de exemplo, gastroparesia, refuxo gastroesofágico e distúrbios afins. Os compostos da presente invenção
BRPI0506736-7A 2004-01-07 2005-01-07 Compostos estereoisoéricos para o tratamento de distúrbios gastrointestinais e no sistema nervoso central, e composições BRPI0506736B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US53489204P 2004-01-07 2004-01-07
US60/534,892 2004-01-07
US56093804P 2004-04-09 2004-04-09
US60/560,938 2004-04-09
PCT/US2005/000510 WO2005068461A1 (en) 2004-01-07 2005-01-07 Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders

Publications (3)

Publication Number Publication Date
BRPI0506736A true BRPI0506736A (pt) 2007-05-15
BRPI0506736B1 BRPI0506736B1 (pt) 2018-08-21
BRPI0506736B8 BRPI0506736B8 (pt) 2021-05-25

Family

ID=34798839

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506736-7A BRPI0506736B1 (pt) 2004-01-07 2005-01-07 Compostos estereoisoéricos para o tratamento de distúrbios gastrointestinais e no sistema nervoso central, e composições

Country Status (19)

Country Link
US (2) US7176218B2 (pt)
EP (2) EP1704146B1 (pt)
JP (2) JP5200288B2 (pt)
KR (1) KR101240464B1 (pt)
CN (1) CN101824033B (pt)
AT (1) ATE464308T1 (pt)
AU (2) AU2005205531B2 (pt)
BR (1) BRPI0506736B1 (pt)
CA (1) CA2551686C (pt)
CY (1) CY1110901T1 (pt)
DE (1) DE602005020580D1 (pt)
DK (2) DK1704146T3 (pt)
ES (2) ES2344568T3 (pt)
IL (1) IL176569A (pt)
MX (1) MXPA06007853A (pt)
NO (1) NO337741B1 (pt)
PT (2) PT1704146E (pt)
RU (1) RU2374244C2 (pt)
WO (1) WO2005068461A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
DE602005020580D1 (de) * 2004-01-07 2010-05-27 Aryx Therapeutics Stereoisomere verbindungen und verfahren zur behandlung von erkrankungen des magen-darm-trakts und des zentralen nervensystems
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
CN101258151B (zh) * 2005-08-31 2012-10-10 ARYx医疗有限公司 用于治疗胃肠系统和中枢神经系统疾病的立体异构化合物的合成方法及中间体
RU2418798C2 (ru) * 2005-08-31 2011-05-20 Арикс Терапьютикс, Инк. Способы синтеза и промежуточные соединения при синтезе стереоизомерных соединений, пригодных для лечения желудочно-кишечных расстройств и расстройств центральной нервной системы
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
US20080312291A1 (en) * 2005-12-23 2008-12-18 Udo Bauer Heterocyclic Gaba-b Modulators
US20080085915A1 (en) * 2006-06-23 2008-04-10 Cyrus Becker Compounds and methods for the treatment of gastrointestinal and central nervous system disorders
CN101402633A (zh) 2007-09-11 2009-04-08 上海恒瑞医药有限公司 苯甲酰胺类衍生物、其制备方法及其在医药上的用途
WO2010062959A1 (en) * 2008-11-26 2010-06-03 Aryx Therapeutics, Inc. 5-ht4 receptor agonists for treating irritable bowel syndrome and colonic hypersensitivity
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
PL395470A1 (pl) * 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego
EA201491990A1 (ru) 2012-05-03 2015-02-27 Новартис Аг L-малатная соль 2,7-диазаспиро[4.5]дец-7-иловых производных и их кристаллические формы в качестве агонистов грелиновых рецепторов
BR112016024830A2 (pt) * 2014-05-16 2017-08-15 Raqualia Pharma Inc receptor agonista 5-ht4 para gastroparesia
US10864367B2 (en) 2015-02-24 2020-12-15 Elira, Inc. Methods for using an electrical dermal patch in a manner that reduces adverse patient reactions
US9956393B2 (en) 2015-02-24 2018-05-01 Elira, Inc. Systems for increasing a delay in the gastric emptying time for a patient using a transcutaneous electro-dermal patch
US10335302B2 (en) 2015-02-24 2019-07-02 Elira, Inc. Systems and methods for using transcutaneous electrical stimulation to enable dietary interventions
US10376145B2 (en) 2015-02-24 2019-08-13 Elira, Inc. Systems and methods for enabling a patient to achieve a weight loss objective using an electrical dermal patch
EP3261712B1 (en) 2015-02-24 2024-04-03 Elira, Inc. System for enabling appetite modulation and/or improving dietary compliance using an electro-dermal patch
US20220062621A1 (en) 2015-02-24 2022-03-03 Elira, Inc. Electrical Stimulation-Based Weight Management System
US10765863B2 (en) 2015-02-24 2020-09-08 Elira, Inc. Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy
US11495028B2 (en) * 2018-09-28 2022-11-08 Intel Corporation Obstacle analyzer, vehicle control system, and methods thereof
US10570127B1 (en) * 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
WO2020096911A1 (en) * 2018-11-05 2020-05-14 Renexxion, Llc Methods of producing naronapride trihydrate

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
GB1425706A (en) 1972-06-30 1976-02-18 Wyeth John & Brother Ltd Piperidine derivatives
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
CA1183847A (en) 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
GB8519707D0 (en) * 1985-08-06 1985-09-11 Fordonal Sa Chemical compounds
US4870074A (en) * 1986-04-30 1989-09-26 Dainippon Pharmaceutical Co., Ltd. Substituted benzamide derivatives, for enhancing gastrointestinal motility
NZ225152A (en) * 1987-07-17 1990-04-26 Janssen Pharmaceutica Nv Heterocyclically substituted piperidinyl benzamides as pharmaceuticals
CA1317940C (en) 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US5041454A (en) * 1987-09-25 1991-08-20 Janssen Pharmaceutica N.V. Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US4975439A (en) * 1987-09-25 1990-12-04 Janssen Pharmaceutical N.V. Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
JP3104142B2 (ja) * 1991-02-15 2000-10-30 北陸製薬株式会社 ベンズアミド誘導体
TW243449B (pt) * 1991-02-15 1995-03-21 Hokuriku Pharmaceutical
US5395832A (en) * 1991-02-15 1995-03-07 Hokuriku Seiyaku Co., Ltd. Benzamide derivatives
IT1260485B (it) * 1992-05-29 1996-04-09 Procedimento e dispositivo per il trattamento dell'obesita' di un paziente
EP0651639A4 (en) * 1992-07-07 1996-06-26 Sepracor Inc METHODS OF USING CISAPRIDE (+) FOR THE TREATMENT OF GASTROSOPHAGIC REFLUX AND OTHER DISORDERS.
CA2139638A1 (en) * 1992-07-07 1994-01-20 Nancy M. Gray Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
US5705498A (en) 1992-11-05 1998-01-06 Smithkline Beecham Plc. Piperidine derivatives as 5-HT4 receptor antagonists
US5472866A (en) * 1992-12-24 1995-12-05 Synaptic Pharmaceutical Corporation DNA encoding 5-HT4A serotonin receptors
US5705798A (en) * 1994-12-16 1998-01-06 Mastercard International Inc. System and method for processing a customized financial transaction card
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
US6147093A (en) * 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
JP3529102B2 (ja) 1997-07-11 2004-05-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノート シヤツプ ５−ｈｔ３および５−ｈｔ４介在性障害に有用な（＋）−ノルシサプリド
JPH11292846A (ja) 1998-02-10 1999-10-26 Hokuriku Seiyaku Co Ltd ベンズアミド誘導体及びそれを含有する医薬
AR022338A1 (es) * 1999-02-04 2002-09-04 Hokuriku Pharmaceutical Un compuesto de benzamida, medicamento que lo contiene, y uso para la manufactura de un medicamento para el tratamiento o prevencion de una enfermedad digestiva o para mejorar la movilidad del tracto gastrointestinal.
DE19933926A1 (de) 1999-07-20 2001-01-25 Boehringer Ingelheim Pharma Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
AU2001264817A1 (en) 2000-05-23 2001-12-17 Exhale Therapeutics, Inc. Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans
AU2001275326C1 (en) * 2000-06-07 2006-09-21 Aryx Therapeutics Treatment of gastroesophageal reflux disease using piperidine derivatives
MXPA03000145A (es) * 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
DE602005020580D1 (de) * 2004-01-07 2010-05-27 Aryx Therapeutics Stereoisomere verbindungen und verfahren zur behandlung von erkrankungen des magen-darm-trakts und des zentralen nervensystems

Also Published As

Publication number Publication date
AU2008243243B2 (en) 2011-03-10
CN101824033A (zh) 2010-09-08
US20050197363A1 (en) 2005-09-08
EP2194053A1 (en) 2010-06-09
NO20063568L (no) 2006-08-07
CN101824033B (zh) 2013-02-27
ES2344568T3 (es) 2010-08-31
JP5200288B2 (ja) 2013-06-05
IL176569A (en) 2011-06-30
EP2194053B1 (en) 2013-03-27
RU2006128589A (ru) 2008-02-20
AU2008243243A1 (en) 2008-12-04
KR20060128966A (ko) 2006-12-14
DE602005020580D1 (de) 2010-05-27
IL176569A0 (en) 2006-10-31
US20050176757A1 (en) 2005-08-11
PT2194053E (pt) 2013-07-08
CA2551686A1 (en) 2005-07-28
WO2005068461A1 (en) 2005-07-28
PT1704146E (pt) 2010-06-30
ATE464308T1 (de) 2010-04-15
MXPA06007853A (es) 2007-01-26
ES2415830T3 (es) 2013-07-29
EP1704146A1 (en) 2006-09-27
JP2007517891A (ja) 2007-07-05
US7176218B2 (en) 2007-02-13
BRPI0506736B1 (pt) 2018-08-21
DK1704146T3 (da) 2010-06-28
JP2012102102A (ja) 2012-05-31
AU2005205531B2 (en) 2011-03-17
BRPI0506736B8 (pt) 2021-05-25
CA2551686C (en) 2014-09-23
AU2005205531A1 (en) 2005-07-28
US7282509B2 (en) 2007-10-16
JP5524939B2 (ja) 2014-06-18
CY1110901T1 (el) 2015-06-10
NO337741B1 (no) 2016-06-13
DK2194053T3 (da) 2013-07-01
EP1704146B1 (en) 2010-04-14
KR101240464B1 (ko) 2013-03-08
RU2374244C2 (ru) 2009-11-27

Similar Documents

Publication Publication Date Title
BRPI0506736A (pt) composto estereoisoméricos e métodos para o tratamento de distúrbios gastrointestinais e no sistema nervoso central
BRPI0607017A2 (pt) métodos e composições para o tratamento de condições relacionadas ao snc
NO20081562L (no) Syntetiske metoder og mellomprodukt for stereoisomeriske forbindelser som er nyttige for behandlingen av gastrointestinale og sentralnervesystemersykdommer
CY1117045T1 (el) Ενωσεις κινουκλιδινης ως προσδετες του νικοτινικου υποδοχεα ακετυλχολινης αλφα-7
ATE507224T1 (de) Verfahren und zwischenverbindungen zur herstellung von n4-phenyl-quinazolin-4-amin derivaten
BRPI0417543A (pt) quinolinas úteis no tratamento de doença cardiovascular
ATE450514T1 (de) Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung
CR8696A (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
ATE518846T1 (de) 2-aminooxazolderivate als für die behandlung von schmerzen geeignete trpvl-antagonisten
ATE432930T1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
NO20072060L (no) 2-acylaminotiazolderivater
MX2007016373A (es) Compuestos de piridil y piridonil estereoisomericos y metodos para el tratamiento de trastornos gastrointestinales y del sistema nervioso central.
EA200600737A1 (ru) Соединения и способы для лечения дислипидемии
MY147404A (en) Process for preparation of n-benzoyl-staurosporine
BRPI0509559A (pt) compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos
WO2007013936A3 (en) Method for treating nervous system disorders and conditions
ATE440836T1 (de) Verbindungen
ATE520408T1 (de) Zubereitung zur behandlung von mineralstoffmangel
EA200802400A1 (ru) Полиморфные формы и способ
EA200701797A1 (ru) Соли окаперидона и фармацевтические композиции, содержащие указанные соли
CY1114088T1 (el) Παραγωγα μεθοξυπιπεριδινης για να χρησιμοποιηθουν στην αγωγη γαστρεντερικων διαταραχων και διαταραχων του κεντρικου νευρικου συστηματος
WO2004022041A3 (de) Behandlung nicht allergischer rhinitis durch selektive phosphodiesterase 4-hemmstoffe
ZA200803101B (en) 4-oxadiozolyl-piperidine compounds and use thereof
TW200510363A (en) Use of substituted chromans or thiocromans for the treatment of FGD

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: ARYX THERAPEUTICS (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25A Requested transfer of rights approved

Owner name: ARYX THERAPEUTICS, INC. (US)

B25A Requested transfer of rights approved

Owner name: ARMETHEON, INC. (US)

B25A Requested transfer of rights approved

Owner name: NARONAPRIDE LLC (US)

B25D Requested change of name of applicant approved

Owner name: RENEXXION LLC (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/01/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF